after imatinib was reported to date; yet, the case differs with our case in that the eruption was well-controlled with a dose reduction to 300 mg per day 4 . Ugurel et al. 5 reported that imatinib acts as a dose dependent inducer of the development of LDE and may show mild reactivity to low or intermediate dose (200 to 600 mg/day). However, in this case, the patient suffered from extensive drug eruption in spite of the low dose of 200 mg per day. We present here LDE after imatinib treatment of 400 mg per day to a low dose of 200 mg per day. This case presented that a low dose of imatinib does not always prevent LDE and can induce severe eruption in some patients. We suggest clinicians to keep in mind that all patients taking imatinib mesylate have the possibility of extensive LDE even in a low dose and therefore should carry a close observation. examination revealed a small (0.4×0.4 cm), firm, movable, well-defined submucosal nodule on the inner side of the upper lip (Fig. 1) . We presumed the lesion was a mucocele and performed excisional biopsy. Histopathologic examination revealed heterogeneous lamellated calculi within the lumen of a dilated minor salivary duct. The calculi had a relatively homogenous core with alternating basophilic and eosinophilic bands at the periphery ( Fig. 2A) . The excretory ductal epithelium had undergone squamous metaplasia (Fig. 2B) . These pathological features were consistent with the diagnosis of minor salivary gland sialolithiasis 3, 4 . Sialolithiasis of the minor salivary glands is frequently misdiagnosed, mostly because its frequency, signs, and symptoms are relatively unknown, especially to dermatologists. We should be aware of this disease and consider it as a possible diagnosis when swelling of the oral mucosal tissues is observed in a patient.
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